Drug Trial Radar · NCT03586869
QUILT-3.080: NANT Pancreatic Cancer Vaccine
Last checked: Nov 20, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
3
Actual
Start
Jul 17, 2018
Primary completion
Apr 17, 2019
Study completion Aug 1, 2019
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care (SoC) chemotherapy.
Conditions
- Pancreatic Cancer
Interventions
Aldoxorubicin HClDrug
Aldoxorubicin Hydrochloride
ALT-803Biological
Recombinant human super agonist interleukin-15 (IL-15) complex
ETBX-011Biological
Ad5 \[E1-, E2b-\]-CEA
ETBX-021Biological
Ad5 \[E1-, E2b-\]-HER2
ETBX-051Biological
Ad5 \[E1-, E2b-\]-Brachyury
ETBX-061Biological
Ad5 \[E1-, E2b-\]-MUC1
GI-4000Biological
RAS yeast
GI-6207Biological
Carcinoembryonic Antigen (CEA) yeast
GI-6301Biological
Brachyury yeast
haNK for infusionBiological
NK-92 \[CD16.158V, ER IL-2\]
bevacizumabBiological
Recombinant human anti-Vascular Endothelial Growth Factor (VEGF) IgG1 monoclonal
CapecitabineDrug
5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
CyclophosphamideDrug
2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
FluorouracilDrug
5-fluoro-2,4 (1H,3H)-pyrimidinedione
LeucovorinDrug
L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt
nab-PaclitaxelDrug
Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
OxaliplatinDrug
cis-\[(1 R,2 R)-1,2-cyclohexanediamine-N,N'\] \[oxalato(2-)- O,O'\] platinum
AvelumabBiological
Recombinant human anti-programmed death-ligand 1 (PD-L1) IgG1 monoclonal antibody
SBRTProcedure
Stereotactic Body Radiation Therapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Up to 230 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.